Mounjaro 12.5 mg Injection Pen

Description

Mounjaro 12.5 mg injection pen is a once-weekly injectable dual GLP-1 and GIP receptor agonist containing tirzepatide, designed for adults with type 2 diabetes or obesity seeking advanced metabolic control.

This dose is part of the upper range of Mounjaro therapy, typically following the 10 mg stage, and is intended for patients who have tolerated prior doses and require enhanced blood sugar management and weight loss support.

Key Features:

• Dual incretin therapy (GLP-1 + GIP) for superior glucose and weight management

• Each pen delivers 12.5 mg tirzepatide per injection

• Clinically shown to reduce A1C and promote weight loss (FDA Clinical Overview)

• Once-weekly self-injection for convenience

• Suitable for advanced treatment progression

Mounjaro 12.5 mg Injection Pen Usage Instructions:

• Inject once weekly on the same day

• Administer in the abdomen, thigh, or upper arm

• Rotate injection sites with each dose

• Begin only after completing the 10 mg stage for at least 4 weeks

• Follow your healthcare provider’s dosing instructions

Mounjaro 12.5mg Side Effects:

Side effects may include mild nausea, vomiting, diarrhea, or fatigue. Symptoms typically decrease over time. Consult your doctor or see the FDA Mounjaro Medication Guide for full safety details.

Storage Instructions:

• Store in a refrigerator (36°F–46°F / 2°C–8°C)

• Keep pen in original packaging to protect from light

• Do not freeze